Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 21 peer-reviewed journal articles Updated
Rheumatology

How Does Lupus Affect Black and Hispanic Populations?

At a Glance

Systemic lupus erythematosus disproportionately affects Black and Hispanic populations, leading to earlier diagnoses and more severe symptoms. These groups face higher risks for complications like lupus nephritis. Proactive screening and tailored medical care are crucial for long-term organ health.

Yes, what you have heard is true. Research consistently shows that systemic lupus erythematosus (SLE) disproportionately affects women of color, particularly Black, Hispanic, and Asian populations, compared to White populations [1][2]. In these communities, the disease is more common, patients are often diagnosed at a younger age, and the condition tends to be more severe [3][4]. Because lupus is a chronic condition, developing it earlier in life means living with the disease longer, which can lead to a greater accumulation of damage to the body over time [5].

More Severe Symptoms and Organ Involvement

A major difference in how lupus affects people of color is the frequency and severity of organ involvement.

Kidney Involvement (Lupus Nephritis)
Lupus nephritis is a serious complication where the immune system attacks the kidneys, potentially leading to permanent kidney damage [6]. Black and Hispanic patients are at a significantly higher risk of developing severe lupus nephritis compared to White patients [7][8]. If left unchecked, this inflammation can progress to end-stage renal disease (ESRD), a condition where the kidneys can no longer function on their own [9]. One study found that the rate of newly diagnosed lupus patients going on to develop ESRD was more than four times higher in Black patients than in White patients [8]. Black patients whose lupus began in childhood also face a faster decline in kidney function [10].

However, a diagnosis of lupus nephritis does not mean kidney failure is inevitable. Modern medical treatments, such as targeted immunosuppressant medications, are highly effective at managing this inflammation and preventing long-term damage.

Cardiovascular Risks
In addition to kidney problems, people with lupus are at a heightened risk for cardiovascular issues, such as accelerated heart disease and atherosclerosis (hardening of the arteries) due to chronic inflammation [11][12]. This risk, along with other severe outcomes, is elevated in non-White populations, which can contribute to higher mortality rates [13][14]. Protecting your heart is just as important as protecting your kidneys, which is why your doctors will closely monitor things like your blood pressure and cholesterol alongside your immune system [15].

Why Do These Differences Exist?

The reasons behind these disparities are complex and multifaceted:

  • Genetics: Different genetic factors associated with the risk of complications, like lupus nephritis, vary across ethnic groups [16][17].
  • Socioeconomic Factors & Systemic Barriers: Access to quality healthcare, living in rural areas, and systemic issues like medical bias and delayed diagnoses play a major role in how well lupus is controlled [18][5]. Studies show that when socioeconomic factors are accounted for, some of the differences in severe outcomes (like complications during pregnancy or mortality related to kidney disease) are reduced, highlighting the critical importance of equal access to high-quality care [19][20].
  • Disease Activity: Patients from non-White ethnic backgrounds generally experience higher baseline levels of disease activity and a worse overall prognosis over the course of their illness [4].

Taking Control of Your Care

While these statistics can feel overwhelming, knowing your risks is the best way to protect your body. Because you may be at a higher risk for organ involvement, early detection and proactive, tailored management are essential [21].

  • Know what routine screening looks like: Checking your kidneys isn’t complicated. It usually involves simple, routine, non-invasive urine tests (to check for protein) and blood tests (to check your creatinine levels and kidney function).
  • Build your care team: Because of the high risk for kidney involvement, you may need to see a nephrologist (kidney doctor) alongside your rheumatologist.
  • Protect your organs every day: You can support your kidney and heart health right now by closely managing your blood pressure and discussing any over-the-counter medications (like ibuprofen, which can affect the kidneys) with your doctor before taking them.

Common questions in this guide

Why is lupus often more severe in Black and Hispanic patients?
Black and Hispanic patients often experience more severe lupus due to a combination of genetic factors, higher baseline disease activity, and socioeconomic barriers like delayed diagnoses. These factors can lead to earlier onsets and a higher risk of complications.
What is lupus nephritis and who is at risk?
Lupus nephritis is a severe complication where the immune system attacks the kidneys. Black and Hispanic patients have a significantly higher risk of developing this condition, which makes regular screening with urine and blood tests essential.
What routine tests are used to monitor the kidneys in lupus patients?
Doctors monitor kidney health using non-invasive urine tests to check for protein, and blood tests to measure creatinine levels. These routine screenings help detect early signs of kidney involvement before permanent damage occurs.
Should I see a specialist if I have lupus and am at higher risk for complications?
Because of the elevated risk for kidney and heart involvement, your rheumatologist may recommend adding a nephrologist (kidney doctor) or a cardiologist to your care team to monitor your organ health closely.
Are there over-the-counter medications I should avoid if I have lupus?
You should always discuss over-the-counter medications with your doctor before taking them. Pain relievers like ibuprofen can negatively affect kidney function, which is particularly concerning for lupus patients at risk for kidney damage.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What specific blood and urine tests are we using to monitor my kidneys, and how often will we run them?
  2. 2.Based on my background and current symptoms, do you recommend I see a nephrologist or cardiologist for baseline testing?
  3. 3.Are there any over-the-counter medications, like pain relievers, that I should avoid to protect my kidney function?
  4. 4.What are the earliest signs of a lupus flare or organ involvement that I should look out for and call your office about?
  5. 5.Is my blood pressure currently in a safe range, and what steps should we take if it starts getting high?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

Related questions

Can You Have a Normal Pregnancy with Lupus?Does a Positive ANA Test Mean I Have Systemic Lupus?Does Lupus Increase Your Risk of Heart Disease?How Long Do You Have to Take Prednisone for Lupus?What Are the Eye Side Effects of Hydroxychloroquine?What Are the Emergency Symptoms of Lupus?What Causes a Lupus Flare-Up? Symptoms & TriggersWhat Causes Lupus Brain Fog & How Is It Managed?What Does Foamy Urine Mean With Lupus? Key Warning SignsWhat Is Secondary Sjögren's in Lupus? | Inciteful MedHow Does Childhood-Onset Lupus Differ from Adult Lupus?Cutaneous vs Systemic Lupus: What is the Difference?What is the Difference Between Lupus and Fibro?What Is the Life Expectancy for Someone With Lupus?Why Does Sun Exposure Trigger Lupus Flares?Why Does Systemic Lupus Take So Long to Diagnose?Why is a Kidney Biopsy Needed for Lupus Nephritis?

References

References (21)
  1. 1

    The Incidence and Prevalence of Systemic Lupus Erythematosus in New York County (Manhattan), New York: The Manhattan Lupus Surveillance Program.

    Izmirly PM, Wan I, Sahl S, et al.

    Arthritis & rheumatology (Hoboken, N.J.) 2017; (69(10)):2006-2017 doi:10.1002/art.40192.

    PMID: 28891252
  2. 2

    Epidemiology of systemic lupus erythematosus: an update.

    Stojan G, Petri M

    Current opinion in rheumatology 2018; (30(2)):144-150 doi:10.1097/BOR.0000000000000480.

    PMID: 29251660
  3. 3

    Epidemiology of lupus: an update.

    Lim SS, Drenkard C

    Current opinion in rheumatology 2015; (27(5)):427-32 doi:10.1097/BOR.0000000000000198.

    PMID: 26196375
  4. 4

    Response to: 'Remission or low disease activity as a target in systemic lupus erythematosus' by Ugarte-Gil et al.

    Zen M, Doria A

    Annals of the rheumatic diseases 2019; (78(1)):e4 doi:10.1136/annrheumdis-2017-212911.

    PMID: 29343511
  5. 5

    Item-specific factors associated with damage accrual in systemic lupus erythematosus: insights from a multiethnic, multinational Latin American cohort.

    Mimica M, Padilla O, Pons-Estel G, et al.

    Lupus science & medicine 2025; (12(2)) doi:10.1136/lupus-2025-001570.

    PMID: 40738509
  6. 6

    Lupus Nephritis and Kidney Transplantation: Where Are We Today?

    Wong T, Goral S

    Advances in chronic kidney disease 2019; (26(5)):313-322 doi:10.1053/j.ackd.2019.08.007.

    PMID: 31733715
  7. 7

    Racial and Ethnic Differences in the Prevalence and Time to Onset of Manifestations of Systemic Lupus Erythematosus: The California Lupus Surveillance Project.

    Maningding E, Dall'Era M, Trupin L, et al.

    Arthritis care & research 2020; (72(5)):622-629 doi:10.1002/acr.23887.

    PMID: 31115180
  8. 8

    Incidence of End-Stage Renal Disease Among Newly Diagnosed Systemic Lupus Erythematosus Patients: The Georgia Lupus Registry.

    Plantinga L, Lim SS, Patzer R, et al.

    Arthritis care & research 2016; (68(3)):357-65 doi:10.1002/acr.22685.

    PMID: 26239749
  9. 9

    Impact of Belimumab on Organ Damage in Systemic Lupus Erythematosus.

    Urowitz MB, Aranow C, Asukai Y, et al.

    Arthritis care & research 2022; (74(11)):1822-1828 doi:10.1002/acr.24901.

    PMID: 35439360
  10. 10

    Principles of pediatric lupus nephritis in a prospective contemporary multi-center cohort.

    Vazzana KM, Daga A, Goilav B, et al.

    Lupus 2021; (30(10)):1660-1670 doi:10.1177/09612033211028658.

    PMID: 34219529
  11. 11

    Crosstalk between Inflammation and Atherosclerosis in Rheumatoid Arthritis and Systemic Lupus Erythematosus: Is There a Common Basis?

    Sircana MC, Erre GL, Castagna F, Manetti R

    Life (Basel, Switzerland) 2024; (14(6)) doi:10.3390/life14060716.

    PMID: 38929699
  12. 12

    Postoperative Major Adverse Cardiac Events in Patients With Systemic Lupus Erythematosus.

    Bruera S, Lei X, Blau B, et al.

    ACR open rheumatology 2022; (4(6)):511-519 doi:10.1002/acr2.11424.

    PMID: 35294107
  13. 13

    Causes of Death Among Individuals With Systemic Lupus Erythematosus by Race and Ethnicity: A Population-Based Study.

    Taylor T, Anastasiou C, Ja C, et al.

    Arthritis care & research 2023; (75(1)):61-68 doi:10.1002/acr.24988.

    PMID: 35904969
  14. 14

    Racial Differences in Plasma Microbial Translocation and Plasma Microbiome, Implications in Systemic Lupus Erythematosus Disease Pathogenesis.

    Wen X, Ogunrinde E, Wan Z, et al.

    ACR open rheumatology 2024; (6(6)):365-374 doi:10.1002/acr2.11664.

    PMID: 38563441
  15. 15

    Subclinical atherosclerosis is associated with future cardiovascular events in lupus patients at apparent low cardiovascular risk.

    Mageau A, Arnoult F, Chauveheid MP, et al.

    Lupus 2025; (34(7)):751-756 doi:10.1177/09612033251344200.

    PMID: 40371720
  16. 16

    Genetic contributions to lupus nephritis in a multi-ethnic cohort of systemic lupus erythematous patients.

    Lanata CM, Nititham J, Taylor KE, et al.

    PloS one 2018; (13(6)):e0199003 doi:10.1371/journal.pone.0199003.

    PMID: 29953444
  17. 17

    Recognition of differently expressed genes and DNA methylation markers in patients with Lupus nephritis.

    Liu Z, Liu F, Xie J, et al.

    Journal of translational internal medicine 2024; (12(4)):367-383 doi:10.2478/jtim-2024-0013.

    PMID: 39360156
  18. 18

    Challenges in the care of patients with systemic lupus erythematosus and lupus nephritis in Latin America.

    Elera-Fitzcarrald C, Alarcón GS, Ugarte-Gil MF

    Expert opinion on pharmacotherapy 2025; (26(4)):447-455 doi:10.1080/14656566.2025.2464913.

    PMID: 39918839
  19. 19

    Contribution of Socioeconomic Status to Racial/Ethnic Disparities in Adverse Pregnancy Outcomes Among Women With Systemic Lupus Erythematosus.

    Kaplowitz ET, Ferguson S, Guerra M, et al.

    Arthritis care & research 2018; (70(2)):230-235 doi:10.1002/acr.23263.

    PMID: 28480528
  20. 20

    Survival Disparity of African American Versus Non-African American Patients With ESRD Due to SLE.

    Nee R, Martinez-Osorio J, Yuan CM, et al.

    American journal of kidney diseases : the official journal of the National Kidney Foundation 2015; (66(4)):630-7.

    PMID: 26002293
  21. 21

    Lupus nephritis-related chronic kidney disease.

    Lichtnekert J, Anders HJ

    Nature reviews. Rheumatology 2024; (20(11)):699-711 doi:10.1038/s41584-024-01158-w.

    PMID: 39317803

This page provides educational information about how systemic lupus erythematosus affects different populations and does not replace professional medical advice. Always consult your rheumatologist about your specific risk factors and organ monitoring plan.

Get notified when new evidence is published on Systemic lupus erythematosus.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.